The COVID-19 global pandemic has broken healthcare systems globally and locally in this on-going uncertain time. In that instance, the European Union (EU) was not an exception. The main aim of this study is to highlight the contemporary challenges faced by the pharmaceutical industry in the European Union region (EU). Importantly, this topic is emerging but under-researched in the existing literature. For this reason, this study attempts to bridge the research gap by examining the issues. Methodologically, this study employed a systematic literature review method to generate new knowledge. Our study conducted data analysis with Microsoft Excel software. This study analysed 27 published studies from Web of Science, Scopus, and indexed journals from the top reputed Chartered Association of Business Schools (CABS). Our study highlighted the complexity of EU pharmaceutical industry through the systematic literature review method. The systematic review revealed that the vulnerability of EU pharmaceutical industry, such as default patent system, ineffective research and development (R&D), debate on the role of alliances, low level of expertise in EU health care system and pharmaceutical supply chain management.